This article is from the source 'guardian' and was first published or seen on . The next check for changes will be

You can find the current article at its original source at https://www.theguardian.com/australia-news/2025/may/14/experts-warn-trump-order-demanding-cheaper-medicines-for-us-could-push-up-australian-prices

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
Experts warn Trump order demanding cheaper medicines for US could push up Australian prices Experts warn Trump order demanding cheaper medicines for US could push up Australian prices
(about 8 hours later)
Faced with lower US profits, pharmaceutical companies could demand higher prices elsewhere in the world, or even withdraw products entirely Faced with lower US profits, pharmaceutical companies could demand higher prices elsewhere in the world, or even withdraw products
Donald Trump’s pressure on medicine companies could drive up the cost of Australia’s Pharmaceutical Benefits Scheme (PBS) or see companies withdraw some medicines from Australian shelves , experts have warned. Donald Trump’s pressure on medicine companies could drive up the cost of Australia’s Pharmaceutical Benefits Scheme (PBS) or see companies withdraw some medicines from Australian shelves, experts have warned.
The US president on Monday threatened to force medicine companies to lower their prices in the US, giving them 30 days to cut costs or face more severe action in an executive order.The US president on Monday threatened to force medicine companies to lower their prices in the US, giving them 30 days to cut costs or face more severe action in an executive order.
Faced with lower American profits, companies would be likely to demand higher prices elsewhere in the world and reject the lower prices offered by the Australian government, according to Flinders University health economist Prof Jonathan Karnon.Faced with lower American profits, companies would be likely to demand higher prices elsewhere in the world and reject the lower prices offered by the Australian government, according to Flinders University health economist Prof Jonathan Karnon.
“It’s a pretty high probability,” Karnon said.“It’s a pretty high probability,” Karnon said.
“Either the Australian government will have to pay more, or the Australian consumers won’t have access to as many new pharmaceuticals as they used to have.”“Either the Australian government will have to pay more, or the Australian consumers won’t have access to as many new pharmaceuticals as they used to have.”
Sign up for Guardian Australia’s breaking news emailSign up for Guardian Australia’s breaking news email
Sign up for Guardian Australia’s breaking news emailSign up for Guardian Australia’s breaking news email
Trump’s threats to force down prices and profits should be taken seriously given domestic political pressures in a country where millions of people cannot afford life-saving drugs, said Jared Mondschein, research director at the United States Studies Centre.Trump’s threats to force down prices and profits should be taken seriously given domestic political pressures in a country where millions of people cannot afford life-saving drugs, said Jared Mondschein, research director at the United States Studies Centre.
“Companies may decide that it’s simply not worth their while to be listed in Australia if the price is not high enough, because the United States will say, ‘Look, it’s not fair for you to be giving them that price, but not us,’” Mondschein said.“Companies may decide that it’s simply not worth their while to be listed in Australia if the price is not high enough, because the United States will say, ‘Look, it’s not fair for you to be giving them that price, but not us,’” Mondschein said.
Monday’s executive order did not single out Australia, instead pointing to prices in other countries generally and demanding companies offer comparably low prices to Americans. Monday’s executive order did not single out Australia, instead pointing to prices in other countries generally and demanding companies offer comparably low prices to those offered to Americans.
A report by research organisation Rand found that US drug prices were nearly four times higher on average than those in Australia and nearly three times higher than those in the OECD overall. A report by research organisation Rand found that US drug prices were nearly four times higher, on average, than those in Australia and nearly three times higher than those in the OECD overall.
Mondschein suggested Trump may see the action as politically necessary given his declining approval rating and longstanding calls for cheaper healthcare for Americans.Mondschein suggested Trump may see the action as politically necessary given his declining approval rating and longstanding calls for cheaper healthcare for Americans.
The Albanese government, which campaigned on protecting cheaper PBS medicines, indicated it would not pass on higher prices to Australia consumers. The Albanese government, which campaigned on protecting cheaper PBS medicines, indicated it would not pass on higher prices to Australian consumers.
“Our task is crystal clear: to strengthen Medicare, protect the PBS, deliver generational reform to aged care, and secure the future of the NDIS,” the health minister, Mark Butler, said on Monday.“Our task is crystal clear: to strengthen Medicare, protect the PBS, deliver generational reform to aged care, and secure the future of the NDIS,” the health minister, Mark Butler, said on Monday.
Asked how the government was responding to the new US policy, a spokesperson reaffirmed that affordable medicines and the PBS were “not up for negotiation”.Asked how the government was responding to the new US policy, a spokesperson reaffirmed that affordable medicines and the PBS were “not up for negotiation”.
Labor was on Tuesday assessing how the policy could impact Australian households and industry, as was pharmaceutical industry body Medicines Australia.Labor was on Tuesday assessing how the policy could impact Australian households and industry, as was pharmaceutical industry body Medicines Australia.
Sign up to Breaking News AustraliaSign up to Breaking News Australia
Get the most important news as it breaksGet the most important news as it breaks
after newsletter promotionafter newsletter promotion
“There is a lot that remains unclear,” Medicines Australia said in a statement.“There is a lot that remains unclear,” Medicines Australia said in a statement.
American pressure on Australian pharmaceutical prices arose earlier in 2025 – while the Trump administration was considering its first round of tariffs – when American industry took aim at the PBS not allowing them to charge Australians more and for delays getting their products to market.American pressure on Australian pharmaceutical prices arose earlier in 2025 – while the Trump administration was considering its first round of tariffs – when American industry took aim at the PBS not allowing them to charge Australians more and for delays getting their products to market.
The Pharmaceutical Research and Manufacturers of America (PhRMA) hit back at Trump’s Monday announcement, but continued to demand action against foreign companies.The Pharmaceutical Research and Manufacturers of America (PhRMA) hit back at Trump’s Monday announcement, but continued to demand action against foreign companies.
“Importing foreign prices from socialist countries would be a bad deal for American patients and workers,” the PhRMA president, Stephen J Ubl, said in a statement.“Importing foreign prices from socialist countries would be a bad deal for American patients and workers,” the PhRMA president, Stephen J Ubl, said in a statement.
“To lower costs for Americans, we need to address the real reasons U.S. prices are higher: foreign countries not paying their fair share.” “To lower costs for Americans, we need to address the real reasons US prices are higher: foreign countries not paying their fair share.”
Australia’s pharmaceutical sector, which Westpac estimated sent more than half its exports to the US in 2024, had so far been exempt from US tariffs but the Trump administration in April was investigating further measures.Australia’s pharmaceutical sector, which Westpac estimated sent more than half its exports to the US in 2024, had so far been exempt from US tariffs but the Trump administration in April was investigating further measures.
Australian investors sold pharmaceutical shares on Monday, fearing a more severe executive order, but bought back in on Tuesday after the formal announcement, lifting local drugmakers CSL, Neuret and Telix. Australian investors sold pharmaceutical shares on Monday, fearing a more severe executive order, but bought back on Tuesday after the formal announcement, lifting share prices for local drugmakers CSL, Neuret and Telix.